ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. .
The stock of microcap Bionomics Ltd. rose 103% early Thursday, after the company reported positive results from a mid-stage trial of a treatment for PTSD.
Bionomics (BNOX) Reports Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Bionomics Announces Update On The Α7 Nicotinic Acetylcholine Receptor (Nachr) Positive Allosteric Modulator (Pam) Collaboration With Msd menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Bionomics Ltd (BNOX) Issues Update on the α7 Nicotinic Acetylcholine Receptor PAM Collaboration with MSD streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.